{
    "clinical_study": {
        "@rank": "154790", 
        "arm_group": [
            {
                "arm_group_label": "Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "GZ402665 dose (0,3 mg/kg body weight) once every 2 weeks for 52 weeks"
            }, 
            {
                "arm_group_label": "Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "GZ402665 dose (1,0 mg/kg body weight) once every 2 weeks for 52 weeks"
            }, 
            {
                "arm_group_label": "Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "GZ402665 dose (3,0 mg/kg body weight) once every 2 weeks for 52 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the safety, efficacy, and\n      pharmacokinetics of different doses of recombinant human acid sphingomyelinase (rhASM)\n      administered intravenously every 2 weeks for 52 weeks."
        }, 
        "brief_title": "Safety, Efficacy, and Pharmacokinetics Study of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Sphingomyelin Lipidosis", 
        "condition_browse": {
            "mesh_term": [
                "Lipidoses", 
                "Niemann-Pick Diseases", 
                "Niemann-Pick Disease, Type A", 
                "Niemann-Pick Disease, Type C"
            ]
        }, 
        "detailed_description": {
            "textblock": "One month screening to 60 days screening from the first dose + 30 to 37 days post study\n      safety follow up"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Patients with documented non-neuronopathic acid sphingomyelinase deficiency\n\n          -  The patient has a diffusing capacity of carbon monoxide (DLco) >20% and \u226480% of the\n             predicted normal value.\n\n          -  The patient has a spleen volume \u22656 multiples of normal(MN). A partial splenectomy\n             will be permitted if performed \u22651 year prior to Screening/Baseline and residual\n             spleen volume is \u22656 MN.\n\n          -  The patient who is female and of childbearing potential must have a negative serum\n             pregnancy test for \u03b2-HCG.\n\n          -  Patients must practice true abstinence or use 2 effective forms of contraception\n\n        Exclusion criteria:\n\n          -  The patient is female and pregnant or breast-feeding.\n\n          -  The patient has received an investigational drug within 30 days prior to study\n             enrollment\n\n          -  The patient has a medical condition or any extenuating circumstance that may\n             significantly interfere with study compliance, including all prescribed evaluations\n             and follow-up activities.\n\n          -  The patient has had a major organ transplant\n\n          -  ALT or AST >250 IU/L or total bilirubin >1.5 mg/dL.\n\n          -  The patient is unwilling or unable to abstain from the use of alcohol for 1 day prior\n             to and 3 days after each rhASM infusion for the duration of the study.\n\n          -  The patient requires medications that may decrease rhASM\n\n          -  The patient is unwilling or unable to avoid the use of medications or herbal\n             supplements that may cause or prolong bleeding, or have potential hepatotoxicity\n             within 10 days prior to and 3 days after liver biopsy\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004691", 
            "org_study_id": "DFI12712", 
            "secondary_id": [
                "2010-023953-12", 
                "U1111-1142-5963"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Dose 1", 
                "Dose 2", 
                "Dose 3"
            ], 
            "description": "Pharmaceutical form:Powder for concentrate for solution for infusion\nRoute of administration: intravenous infusion", 
            "intervention_name": "GZ402665", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 4, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Multi-Center, Randomized, Open-Label, Repeat Dose, Dose-Comparison Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency", 
        "overall_contact": {
            "email": "Contact-US@sanofi.com", 
            "last_name": "Trial Transparency Team"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage change in spleen volume", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 52"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004691"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Liver Volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52"
            }, 
            {
                "measure": "Participants with Pulmonary imaging and function tests", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52"
            }, 
            {
                "measure": "Exercise capacity by cycle ergometry", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52"
            }, 
            {
                "measure": "Hematology", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52"
            }, 
            {
                "measure": "Physician Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52"
            }, 
            {
                "measure": "Efficacy biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 52"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}